IMI Pengajuan SEC - Intermolecular, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1311241

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intermolecular, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 30, 2019	15-12B	IMI / Intermolecular, Inc. 15-12B - - FORM 15-12B Form 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35348 INTERMOLECULAR, INC. (Exact name of registrant as spe
September 24, 2019	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 9 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 23, 2019	S-8 POS	IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 20, 2019	EX-3.2	Amended and Restated Bylaws of Intermolecular, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF INTERMOLECULAR, INC. ARTICLE I STOCKHOLDERS SECTION 1.1. ANNUAL MEETINGS. An annual meeting of stockholders shall be held, either within or without the State of Delaware, on the last Friday of April of each year, beginning in the year 2020, for the purpose of electing directors and for the transaction of such other business as may come before the
September 20, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Intermolecular, Inc. EX-3.1 Exhibit 3.1 EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTERMOLECULAR, INC. ARTICLE ONE The name of the corporation is Intermolecular, Inc. (the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, Delaware 19808, New Castle County. The name of its registered agent at that address is C
September 20, 2019	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commi
August 14, 2019	EX-99.1	Joint Filing Agreement EX-99.1 2 tv527504ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing on their behalf of Amendment No. 1 to Schedule 13D and any amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share, of Intermole
August 14, 2019	SC 13D/A	IMI / Intermolecular, Inc. / Merck Kgaa - SC 13D/A Activist Investment SC 13D/A 1 tv527504sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) INTERMOLECULAR, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D109 (CUSIP Number) David A. Martland, Esq. Nixon Peabody LLP 53 State Street Boston, MA 02109 (617)
August 8, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 8, 2019	EX-99.1	Intermolecular Reports Second Quarter 2019 Financial Results Exhibit 99.1 Intermolecular Reports Second Quarter 2019 Financial Results SAN JOSE, Calif., August 8, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2019. Second Quarter of 2019 Financial Results Revenue for the second quarter of 2019 was $4.6 million, a decrease of 31% from $6.7 million
August 8, 2019	10-Q	IMI / Intermolecular, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolecu
July 17, 2019	EX-99.1	Intermolecular Stockholders Approve Merck KGaA, Darmstadt, Germany’s Proposed Acquisition of Intermolecular EX-99.1 Exhibit 99.1 News Release July 17, 2019 Intermolecular Stockholders Approve Merck KGaA, Darmstadt, Germany’s Proposed Acquisition of Intermolecular SAN JOSE, California, July 17, 2019 — Intermolecular, Inc. (NASDAQ: IMI) announced today that the stockholders of Intermolecular have approved the previously announced proposed acquisition of all outstanding shares of common stock of Intermolec
July 17, 2019	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 d766472d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor
June 28, 2019	DEFA14A	IMI / Intermolecular, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo
June 12, 2019	DEFM14A	IMI / Intermolecular, Inc. DEFM14A - - DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 28, 2019	PREM14A	IMI / Intermolecular, Inc. PREM14A - - PRELIMINARY PROXY STATEMENT PERTAINING TO A MERGER Preliminary Proxy Statement pertaining to a Merger Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 16, 2019	SC 13D	IMI / Intermolecular, Inc. / Merck Kgaa - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) INTERMOLECULAR, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D109 (CUSIP Number) David A. Martland, Esq. Nixon Peabody LLP 53 State Street Boston, MA 02109 (617) 345-1000 (Name, Address and Telephone Nu
May 16, 2019	SC 13D	IMI / Intermolecular, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorize
May 16, 2019	EX-99.1	Joint Filing Agreement EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share, of Intermolecular, Inc. and further agrees that this Joint Filin
May 14, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 14, 2019	EX-99.1	Intermolecular Reports First Quarter 2019 Financial Results Exhibit 99.1 Intermolecular Reports First Quarter 2019 Financial Results SAN JOSE, Calif., May 14, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, 2019. Q1 2019 Financial and Operational Highlights • Program revenue totaled $6.4 million or 96% of total revenue of $6.7 million. • Gross pro
May 14, 2019	10-Q	IMI / Intermolecular, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolec
May 7, 2019	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - EXHIBIT 99.1 - COMPANY STOCKHOLDER SUPPORT AGREEMENT, DATED MAY 6, 2019 Activist Investment begin 644 ex991to13da807738042050719.pdf M)5!$1BTQ+C4-)>+CS],-"C@U(# @;V)J#3P\+TQI;F5A%LX-2 S M-UTO26YF;R X-" P(%(O3&5N9W1H(#$P,2]07!E+UA2968O5ULQ(#,@,5T^/G-T\U& MATP7\DX0K ":T58]/7IWYG\NLLS(GYX6H;FQH:4;%TX+ M@8EES[=BBPRZ<=VNA&O:L9T/@1)F)3R;EF[7!E+T-A=&%L;V<^ M/@UE;F1O8FH-.#<@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E M9$)O>%LP(# @-C$R(#%LP(# @-C$R(#%LP(# @ M-C$R(#3BD)PM6=+F+5J=)=P# M#">GU;H%Y7S
May 7, 2019	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 8 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH
May 6, 2019	DEFA14A	IMI / Intermolecular, Inc. DEFA14A DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
May 6, 2019	DFAN14A	IMI / Intermolecular, Inc. DFAN14A DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
May 6, 2019	EX-2.2	Form of Support Agreement, by and between EMD Group Holding II, Inc. and certain stockholders of Intermolecular, Inc. EX-2.2 Exhibit 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of [●], 2019 (this “Agreement”), by and between EMD Group Holding II, Inc., a Delaware corporation (“Parent”), and the stockholder identified on the signature pages hereto (the “Stockholder”). WHEREAS, concurrently herewith, Intermolecular, Inc., a Delaware corporation (“Indigo”), EMD P
May 6, 2019	EX-99.3	3011 N. First Street, San Jose, CA 95134 EX-99.3 Exhibit 99.3 May 6, 2019 Dear [ Customer Name ]: We are pleased to announce today that Intermolecular (“IMI”) has entered into a definitive agreement pursuant to which IMI will become a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany (“Merck KGaA”). As a result of the planned integration of these leading technology innovators, the two companies expect to be able to provide a more
May 6, 2019	EX-2.1	Agreement and Plan of Merger, dated as of May 6, 2019, by and among EMD Group Holding II, Inc., EMD Performance Material Semiconductor Services Corp. and Intermolecular, Inc. EX-2.1 2 d666010dex21.htm EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among EMD GROUP HOLDING II, INC., EMD PERFORMANCE MATERIALS SEMICONDUCTOR SERVICES CORP. and INTERMOLECULAR, INC. Dated as of May 6, 2019 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 The Effective Time 2 1.3 The Closing 2 1.4 Effect of the
May 6, 2019	EX-99.2	Email to EX-99.2 5 d666010dex992.htm EX-99.2 Exhibit 99.2 Email to All-Company from CEO Chris Kramer IMPORTANT: Please read & attend a Company All-Hands meeting at 11:00 AM (PDT) Dear Colleagues, In our time together at IMI, you and I have repeatedly addressed many challenges to make our company better and to help achieve our objectives. You have embraced our PACE values and handled change with courage and
May 6, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Intermolecular, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35348 20-1616267 (State or other jurisdiction of incorporation) (Commission Fi
May 6, 2019	EX-99.1	Page 2 of 4 EX-99.1 Exhibit 99.1 News Release May 6, 2019 Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction • Acquisition to strengthen technology offering and diversify performance materials portfolio of Merck KGaA, Darmstadt, Germany • Transaction expected to close in the second half of 2019 San Jose, California, May 6, 2019 – Intermolecular, Inc.
May 6, 2019	EX-99.2	Letter to Intermolecular employees, dated as of May 6, 2019 EX-99.2 Exhibit 99.2 Email to All-Company from CEO Chris Kramer IMPORTANT: Please read & attend a Company All-Hands meeting at 11:00 AM (PDT) Dear Colleagues, In our time together at IMI, you and I have repeatedly addressed many challenges to make our company better and to help achieve our objectives. You have embraced our PACE values and handled change with courage and confidence. Today we are an
May 6, 2019	EX-2.1	Agreement and Plan of Merger, dated as of May 6, 2019, by and among EMD Group Holding II, Inc., EMD Performance Material Semiconductor Services Corp. and Intermolecular, Inc. EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among EMD GROUP HOLDING II, INC., EMD PERFORMANCE MATERIALS SEMICONDUCTOR SERVICES CORP. and INTERMOLECULAR, INC. Dated as of May 6, 2019 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 The Effective Time 2 1.3 The Closing 2 1.4 Effect of the Merger 2 1.5 Certificate
May 6, 2019	DEFA14A	IMI / Intermolecular, Inc. DEFA14A 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Intermolecular, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35348 20-1616267 (State or other jurisdiction of incorporation) (Commission Fi
May 6, 2019	EX-2.2	Form of Support Agreement, by and between EMD Group Holding II, Inc. and certain stockholders of Intermolecular, Inc. EX-2.2 Exhibit 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of [●], 2019 (this “Agreement”), by and between EMD Group Holding II, Inc., a Delaware corporation (“Parent”), and the stockholder identified on the signature pages hereto (the “Stockholder”). WHEREAS, concurrently herewith, Intermolecular, Inc., a Delaware corporation (“Indigo”), EMD P
May 6, 2019	EX-99.1	Press Release issued by Intermolecular, Inc. on May 6, 2019 EX-99.1 Exhibit 99.1 News Release May 6, 2019 Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction • Acquisition to strengthen technology offering and diversify performance materials portfolio of Merck KGaA, Darmstadt, Germany • Transaction expected to close in the second half of 2019 San Jose, California, May 6, 2019 – Intermolecular, Inc.
May 6, 2019	EX-99.3	Letter to Intermolecular customers, dated as of May 6, 2019 EX-99.3 Exhibit 99.3 May 6, 2019 Dear [ Customer Name ]: We are pleased to announce today that Intermolecular (“IMI”) has entered into a definitive agreement pursuant to which IMI will become a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany (“Merck KGaA”). As a result of the planned integration of these leading technology innovators, the two companies expect to be able to provide a more
April 29, 2019	10-K/A	IMI / Intermolecular, Inc. 10-K/A (Annual Report) 10-K/A 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 3, 2019	SC 13G/A	IMI / Intermolecular, Inc. / Subin Neil S - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) March 29, 2019 (Date of Event which Requires
April 2, 2019	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 7 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da70773804204022019.htm AMENDMENT NO. 7 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C
April 2, 2019	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecular, Inc. This Joint Filing Agreement shall be filed as an Exhib
March 8, 2019	S-8	IMI / Intermolecular, Inc. S-8 S-8 1 imi-s8.htm S-8 As filed with the Securities and Exchange Commission on March 8, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organ
March 8, 2019	10-K	IMI / Intermolecular, Inc. 10-K (Annual Report) 10-K 1 imi-10k20181231.htm 10-K Of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi
February 12, 2019	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20190212.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
February 12, 2019	EX-99.1	Intermolecular Reports Fourth Quarter and Full Year 2018 Financial Results 2018 Marked First Full Year of Positive Adjusted EBITDA Since 2013 Positive Operating Cash Flow of $5.9 million in 2018 Exhibit 99.1 Intermolecular Reports Fourth Quarter and Full Year 2018 Financial Results 2018 Marked First Full Year of Positive Adjusted EBITDA Since 2013 Positive Operating Cash Flow of $5.9 million in 2018 SAN JOSE, Calif., February 12, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for the fourth quarter and full year end
February 8, 2019	SC 13G/A	IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv512571sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 6)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2018 (
February 1, 2019	SC 13G/A	IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d698243dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check t
December 28, 2018	8-K	Current Report 8-K 1 d679096d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 26, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 (State or Other Jurisdiction of Incorporation) (C
November 6, 2018	EX-99.1	Intermolecular Reports Third Quarter and Nine Month 2018 Financial Results Fifth Consecutive Quarter of Positive Adjusted EBITDA; Secured Major New Program Service Agreement with New Leading Semiconductor Manufacturer; Board of Directors Approves $10 Exhibit 99.1 Intermolecular Reports Third Quarter and Nine Month 2018 Financial Results Fifth Consecutive Quarter of Positive Adjusted EBITDA; Secured Major New Program Service Agreement with New Leading Semiconductor Manufacturer; Board of Directors Approves $10 Million Share Repurchase Program SAN JOSE, Calif., November 6, 2018 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanc
November 6, 2018	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20181102.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inc
November 6, 2018	10-Q	IMI / Intermolecular, Inc. 10-Q (Quarterly Report) 10-Q 1 imi-10q20180930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
August 6, 2018	EX-99.1	Intermolecular Reports Second Quarter 2018 Financial Results Program Revenue Up 45% Year-over-Year, Driving Net Income of $0.5 million and 19% Adjusted EBITDA Margin Exhibit 99.1 Intermolecular Reports Second Quarter 2018 Financial Results Program Revenue Up 45% Year-over-Year, Driving Net Income of $0.5 million and 19% Adjusted EBITDA Margin SAN JOSE, Calif., August 6, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2018. Q2 2018 Financial and Operat
August 6, 2018	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 6, 2018	10-Q	IMI / Intermolecular, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolecu
May 25, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 imi-8k20180524.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo
May 11, 2018	8-K	Current Report 8-K 1 imi-8k20180515.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 09, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo
May 8, 2018	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20180508.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpor
May 8, 2018	EX-99.1	Intermolecular Reports First Quarter 2018 Financial Results Company Achieves Third Consecutive Quarter of Positive Adjusted EBITDA Exhibit 99.1 Intermolecular Reports First Quarter 2018 Financial Results Company Achieves Third Consecutive Quarter of Positive Adjusted EBITDA SAN JOSE, Calif., May 8, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, 2018. Q1 2018 Financial and Operational Highlights • Total revenue of $9
May 8, 2018	10-Q	IMI / Intermolecular, Inc. 10-Q (Quarterly Report) 10-Q 1 imi-10q20180331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
April 10, 2018	DEFA14A	IMI / Intermolecular, Inc. DEFA14A DEFA14A 1 imi-defa14a20171231.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
April 10, 2018	DEF 14A	IMI / Intermolecular, Inc. DEF 14A DEF 14A 1 imi-def14a20180524.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
March 2, 2018	S-8	IMI / Intermolecular, Inc. S-8 As filed with the Securities and Exchange Commission on March 2, 2018 Registration No.
March 2, 2018	10-K	IMI / Intermolecular, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35348 Intermolecular
February 13, 2018	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) EX-99.1 2 imi-ex9916.htm EX-99.1 Exhibit 99.1 Intermolecular Reports Fourth Quarter and Full Year 2017 Financial Results SAN JOSE, Calif., February 13, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its fourth quarter and full year ended December 31, 2017. Results Highlights: • Fourth quarter total revenue of $10.5 milli
February 13, 2018	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20180213.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
February 12, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
February 12, 2018	SC 13G/A	IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d519666dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check t
January 31, 2018	SC 13G/A	IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 tv483954sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 5)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2017 (Date o
January 23, 2018	SC 13G	IMI / Intermolecular, Inc. / Subin Neil S - SC 13G Passive Investment SC 13G 1 tv483742sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) January 12, 2
November 2, 2017	10-Q	Intermolecular 10-Q (Quarterly Report) 10-Q 1 imi-10q20170930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
November 2, 2017	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, Unaudited) EX-99.1 2 imi-ex9916.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2017 Financial Results SAN JOSE, Calif., November 2, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Third Quarter ended September 30, 2017. Results Highlights: • Positive third quarter adjusted EBITDA on 7% sequential revenue growth • Third quarter total revenue of $8.6 million • Five new
November 2, 2017	8-K	Results of Operations and Financial Condition imi-8k20171102.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation
November 2, 2017	8-K	Current Report imi-8k20171031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation
October 10, 2017	8-K	Current Report 8-K 1 imi-8k20171009.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
September 5, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement 8-K 1 imi-8k20170904.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 04, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I
August 25, 2017	CORRESP	Intermolecular ESP CORRESP August 25, 2017 VIA FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 3030 Washington, D.
August 8, 2017	10-Q	Intermolecular 10-Q (Quarterly Report) imi-10q20170630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0
August 8, 2017	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20170808.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor
August 8, 2017	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, Unaudited) imi-ex9916.htm Exhibit 99.1 Intermolecular Announces Second Quarter 2017 Financial Results SAN JOSE, Calif., August 8, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Second Quarter ended June 30, 2017. Results Highlights: • Second quarter total revenue of $8.1 million • Three new customer contracts signed during the quarter • Net cash position remains strong at $27.0 mill
May 17, 2017	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 imi-8k20170516.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo
May 15, 2017	SC 13G/A	IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) May 11, 2017 (Date of Event which Requires F
May 4, 2017	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 4, 2017	10-Q	Intermolecular IMI-Q1-20170331 (Quarterly Report) 10-Q 1 imi-10q20170331.htm IMI-Q1-20170331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
May 4, 2017	8-K	Results of Operations and Financial Condition imi-8k20170504.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Co
May 4, 2017	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, Unaudited) imi-ex9916.htm Exhibit 99.1 Intermolecular Announces First Quarter 2017 Financial Results SAN JOSE, Calif., May 4, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its first Quarter ended March 31, 2017. Results Highlights: • First quarter total revenue of $9.9 million • Implemented cost reductions to enable positive Adjusted EBITDA at $10 million revenue per quarter • New cust
May 4, 2017	EX-10.4	Separation Agreement by and between Intermolecular, Inc. and C. Richard Neely, Jr Exhibit 10.4 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between C. Richard Neely, Jr. (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and st
May 4, 2017	EX-10.3	Separation Agreement by and between Intermolecular, Inc. and Bruce McWilliams. Exhibit 10.3 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Dr. Bruce M. McWilliams (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and
May 4, 2017	EX-10.1	Amended and Restated Change in Control and Severance Agreement EX-10.1 2 imi-ex101220.htm EX-10.1 Exhibit 10.1 INTERMOLECULAR, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Bill Roeschlein (“Executive”) and Intermolecular, Inc. (the “Company”), effective as of April 3, 2017 (the “Effective Date”). R E C I T A L S
May 4, 2017	EX-10.2	Offer Letter by and between Intermolecular, Inc. and Bill Roeschlein EX-10.2 3 imi-ex102219.htm EX-10.2 Exhibit 10.2 March 29, 2017 Bill Roeschlein Intermolecular, Inc. 3011 N. First Street San Jose, CA 95134 Dear Bill: On behalf of Intermolecular, Inc. (the “Company”), I set forth the certain terms of your updated employment with the Company: 1.Effective April 3, 2017, you will serve on a full-time basis as the Company’s Chief Financial Officer and principal finan
April 11, 2017	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
April 5, 2017	DEFA14A	Intermolecular DEFA14A DEFA14A 1 imi-defa14a20170516.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
April 5, 2017	DEF 14A	Intermolecular DEF 14A DEF 14A 1 imi-def14a20170516.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
March 30, 2017	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13da607738042033017.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu
March 30, 2017	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 6 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da60773804203302017.htm AMENDMENT NO. 6 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C
March 29, 2017	8-K	Intermolecular FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commissio
March 3, 2017	S-8	Intermolecular S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. First Street San Jose, CA 95134 (A
March 3, 2017	10-K	Intermolecular 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35348 Intermolecular
March 1, 2017	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
February 13, 2017	SC 13G/A	IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d345799dsc13ga.htm SC 13G/A CUSIP No. 45882D109 Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires
February 13, 2017	SC 13G/A	IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v458831sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of
February 10, 2017	SC 13G	IMI / Intermolecular, Inc. / Cowen Prime Services LLC Passive Investment SC 13G 1 s22-1771213g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 9, 2017	8-K	Results of Operations and Financial Condition 8-K 1 imi-8k20170209.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inc
February 9, 2017	EX-99	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) EX-99 2 imi-ex996.htm EX-99 Exhibit 99.1 Intermolecular Announces Fourth Quarter 2016 and Full Year 2016 Financial Results SAN JOSE, Calif., February 9, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its fourth quarter and full year ended December 31, 2016. Results Highlights: • Fourth quarter total revenue of $10.5 million; 2016 fiscal year revenue of $47.3 million, with 201
January 30, 2017	SC 13G/A	Intermolecular SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 v457592sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) Decemb
December 22, 2016	8-K	Current Report 8-K 1 imi-8k20161222.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
November 17, 2016	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 5 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da50773804211172016.htm AMENDMENT NO. 5 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C
November 16, 2016	EX-10.1	Governance Agreement by and between Intermolecular, Inc. and Raging Capital Management, LLC imi-ex10143.htm Exhibit 10.1 GOVERNANCE AGREEMENT This GOVERNANCE AGREEMENT is made and entered into as of November 14, 2016 (the ?Agreement?) by and between Intermolecular, Inc., a Delaware corporation (the ?Company?), and Raging Capital Management, LLC, a Delaware limited liability company (the ?Investor?). The Company and the Investor are referred to herein as the ?Parties.? WHEREAS, the Invest
November 16, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
November 14, 2016	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH
November 14, 2016	EX-99.1	GOVERNANCE AGREEMENT Exhibit 99.1 GOVERNANCE AGREEMENT This GOVERNANCE AGREEMENT is made and entered into as of November 14, 2016 (the “Agreement”) by and between Intermolecular, Inc., a Delaware corporation (the “Company”), and Raging Capital Management, LLC, a Delaware limited liability company (the “Investor”). The Company and the Investor are referred to herein as the “Parties.” WHEREAS, the Investor beneficially
November 2, 2016	10-Q	Intermolecular IMI-Q3-20160930 (Quarterly Report) 10-Q 1 imi-10q20160930.htm IMI-Q3-20160930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
November 2, 2016	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) imi-ex9916.htm Exhibit 99.1 Intermolecular Announces Third Quarter 2016 Financial Results SAN JOSE, Calif., November 2, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its third quarter of fiscal 2016 ended September 30, 2016. Results Highlights: ? Third quarter total revenue finished at $10.6 million, with program revenue growing 2% year-over-year ? Significant cost reduction
November 2, 2016	8-K	Intermolecular 8-K (Current Report/Significant Event) imi-8k20161102.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation
November 2, 2016	EX-10.30	Separation Agreement by and between Intermolecular, Inc. and Scot A. Griffin. Exhibit 10.30 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Scot A. Griffin (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and status
November 2, 2016	EX-10.11D	Change in Control and Severance Agreement between Intermolecular, Inc. and Christian Kramer Exhibit 10.11d INTERMOLECULAR, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Christian Kramer (“Executive”) and Intermolecular, Inc. (the “Company”), effective as of the date of the closing of the Company’s initial public offering of shares of its common stock (the “Effective Date”). R E C I T
November 2, 2016	EX-10.29	3011 North First Street, San Jose, CA 95134 (408) 582-5700 / (408) 582-5179 fax Exhibit 10.29 July 27, 2016 Christian Kramer [home address] Re:Intermolecular, Inc. Offer Letter Dear Chris: Intermolecular, Inc. (the “Company”) is pleased to formally extend to you an offer of employment for the position of Chief Executive Officer and President, reporting to the Bruce McWilliams, Executive Chairman. You will be based at Company’s offices in San Jose, California. To compensate yo
September 22, 2016	8-K	Current Report 8-K 1 imi-8k20160916.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I
August 11, 2016	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH
August 4, 2016	10-Q	Intermolecular IMI-Q2-20160630 (Quarterly Report) 10-Q 1 imi-10q20160630.htm IMI-Q2-20160630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C
August 4, 2016	8-K	Results of Operations and Financial Condition 8-K 1 d221263d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
August 4, 2016	EX-99.2	Intermolecular Appoints Chris Kramer President and CEO Bruce McWilliams becomes Executive Chairman EX-99.2 3 d221263dex992.htm EX-99.2 Exhibit 99.2 Intermolecular Appoints Chris Kramer President and CEO Bruce McWilliams becomes Executive Chairman SAN JOSE, Calif., August 4, 2016 — Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today announced that Chris Kramer has been appointed as President and Chief Executive Officer reporting to Bruce McWilliams, w
August 4, 2016	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue: Program revenue $ 10,052 $ 7,251 $ 22,013 $ 14 EX-99.1 2 d221263dex991.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Second Quarter 2016 Financial Results SAN JOSE, Calif., August 4, 2016 — Intermolecular, Inc. (NASDAQ: IMI) today reported results for its second quarter of fiscal 2016 ended June 30, 2016. Results Highlights: • Second quarter revenue of $11.7 million, 7% year-over-year growth, 39% year-over-year program revenue growth • Tot
May 27, 2016	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 imi-20160525x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorp
May 27, 2016	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da20773804205252016.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C
May 27, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13da207738042052516.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu
May 5, 2016	10-Q	Intermolecular 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
May 5, 2016	8-K	Results of Operations and Financial Condition 8-K 1 imi-20160505x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo
May 5, 2016	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) imiEx991 Exhibit 99.1 Intermolecular Announces First Quarter 2016 Financial Results SAN JOSE, Calif., May 5, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its first quarter of fiscal 2016 ended March 31, 2016. Results Highlights: ? First quarter revenue of $14.5 million, 47% year-over-year growth ? Second consecutive quarter of positive EBITDA First Quarter Fiscal 2016 Resul
April 12, 2016	DEFA14A	Intermolecular DEFA14A DEFA14A 1 imi-20160525xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only
April 12, 2016	DEF 14A	Intermolecular DEF 14A imiCurrent folioDEF14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 11, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13da107738042041116.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu
April 11, 2016	SC 13D/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da10773804204112016.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C
April 1, 2016	EX-16.1	April 1, 2016 EX-16.1 2 c241-20160401ex161b0f3be.htm EX-16.1 Exhibit 16.1 April 1, 2016 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Intermolecular, Inc. and, under the date of March 28, 2016, we reported on the consolidated financial statements of Intermolecular, Inc. as of and for the years ended December 31, 2015 and 2014, and th
April 1, 2016	8-K	Current Report 8-K 1 c241-20160401x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2016 (March 29, 2016) Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jur
March 28, 2016	S-8	Intermolecular S-8 S-8 1 imi-20160328xs8.htm S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. Firs
March 28, 2016	EX-99.1	Intermolecular Files Fiscal Year 2015 Financial Statements EX-99.1 2 imi-20160328ex99122e718.htm EX-99.1 Exhibit 99.1 Intermolecular Files Fiscal Year 2015 Financial Statements SAN JOSE, Calif., March 28, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today filed its annual report on Form 10-K for the full year ended December 31, 2015. The Company’s Form 10-K reports fourth quarter and annual revenues of $13.0 million and $45.3 million, respectively, instead o
March 28, 2016	8-K	Regulation FD Disclosure 8-K 1 imi-20160328x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
March 28, 2016	10-K	Intermolecular 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35
February 10, 2016	SC 13G/A	IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Amendment No. #1 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) DECEMBER 31, 2015 (Da
February 9, 2016	SC 13G	IMI / Intermolecular, Inc. / Cowen Prime Services LLC - SCHEDULE 13G Passive Investment SC 13G 1 s22-1661713g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design
February 4, 2016	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) imiEx991 Exhibit 99.1 Intermolecular Reports Fourth Quarter 2015 and Full Year 2015 Financial Results Results Highlights: · Positive fourth quarter operating cash flow · Fourth quarter revenue of $13.5 million, 17% quarter-on-quarter growth SAN JOSE, Calif., February 4, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its fourth quarter and full year ended December 31, 2015. Fo
February 4, 2016	8-K	Results of Operations and Financial Condition imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 3, 2016	SC 13G/A	IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v430377sc13g-a.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2015 (Date
February 2, 2016	SC 13G/A	IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2015 (Date of Event which Requi
November 23, 2015	8-K	Intermolecular 8-K (Current Report/Significant Event) imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 23, 2015	EX-99.1	Intermolecular Announces EX-99.1 2 imi-20151117ex991997938.htm EX-99.1 Exhibit 99.1 Intermolecular Announces New Developments in Its Relationship with Micron SAN JOSE, Calif., November 23, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced that its Collaborative Development Program (“CDP”) agreement with Micron Technology, Inc. (“Micron”) will conclude on April 1, 2016
November 6, 2015	EX-99.2	November 05, 2015, Intermolecular, Inc. Q3 Earnings Call EX-99.2 3 imi-20151105ex992a0c27e.htm EX-99.2 November 05, 2015, Intermolecular, Inc. Q3 Earnings Call CORPORATE PARTICIPANTS Rick Neely Intermolecular, Inc. - SVP & CFO Bruce McWilliams Intermolecular, Inc. - President & CEO CONFERENCE CALL PARTICIPANTS Edwin Mok Needham & Company - Analyst Gus Richard Northland Capital Markets - Analyst PRESENTATION Operator Good day, ladies and gentlemen, and w
November 6, 2015	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) EX-99.1 2 imi-20151105ex991a3e2a0.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2015 Results SAN JOSE, Calif., November 5, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced results for its third quarter ended September 30, 2015 Third Quarter Fiscal 2015 Results Revenue for the third quarter of 2015 was $11.5 million, compared
November 6, 2015	8-K/A	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporatio
November 5, 2015	8-K	Results of Operations and Financial Condition 8-K 1 c241-20151105x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I
November 5, 2015	8-K/A	Results of Operations and Financial Condition 8-K/A 1 imi-20151105x8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or
November 5, 2015	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) EX-99.1 2 imi-20151105ex991eb9047.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2015 Results SAN JOSE, Calif., November 5, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced results for its third quarter ended September 30, 2015 Third Quarter Fiscal 2015 Results Revenue for the third quarter of 2015 was $11.5 million, compared
August 11, 2015	8-K	Current Report 8-K 1 imi-20150811x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
August 6, 2015	8-K	Results of Operations and Financial Condition 8-K 1 imi-20150806x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
August 6, 2015	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) 20150806EX991 Exhibit 99.1 Intermolecular Announces Second Quarter 2015 Results SAN JOSE, Calif., August 6, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - accelerating research and development (R&D) for advanced materials - today announced results for its second quarter ended June 30, 2015. Second Quarter Fiscal 2015 Results Revenue for the second quarter of 2015 was $11.0 million, compared to $9.9 m
July 27, 2015	8-K	Intermolecular 8-K (Current Report/Significant Event) imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 1, 2015	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13d0773804206242015.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu
July 1, 2015	SC 13D	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSHA
July 1, 2015	EX-24.1	POWER OF ATTORNEY Unassociated Document Exhibit 24 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints Allan J.
July 1, 2015	EX-99.2	POWER OF ATTORNEY Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints Allan J. Young signing singly, the undersigned’s true and lawful attorney-in-fact to: 1. Execute for and on behalf of the undersigned all documents relating to the business of Raging Capital Management, LLC, including, but not limited to, all filings with the Securities and Excha
May 29, 2015	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 c241-20150529x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor
May 7, 2015	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) EX-99.1 2 c241-20150506ex9910a26d9.htm EX-99.1 Exhibit 99.1 Intermolecular Announces First Quarter 2015 Results SAN JOSE, Calif., May, 2015 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended March 31, 2015. First Quarter Fiscal 2015 Results Revenue for the first quarter o
May 7, 2015	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 10, 2015	DEF 14A	Intermolecular DEF 14A imiCurrent folio14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 10, 2015	DEFA14A	Intermolecular DEFA14A DEFA14A 1 imi-20150527xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only
March 19, 2015	SC 13G	IMI / Intermolecular, Inc. / ENTEGRIS INC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.
February 27, 2015	S-8	IMI / Intermolecular, Inc. S-8 - - S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. First Street San Jose, CA 95134 (A
February 17, 2015	SC 13G/A	IMI / Intermolecular, Inc. / Park West Asset Management LLC - SC 13G/A Passive Investment SC 13G/A 1 intermolsch13gam3dec312014.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERMOLECULAR INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statem
February 17, 2015	SC 13G/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 10 9 (CUSIP Number) D
February 12, 2015	8-K	Results of Operations and Financial Condition 8-K 1 a8k-2014q4earningsrelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi
February 12, 2015	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended December 31, Years Ended December 31, 2014 2013 2014 2013 Revenue: Collaborative development program and servi EX-99.1 2 a8-k2014q4xex991.htm EXHIBIT 99.1 Exhibit 99.1 Intermolecular Announces Full Year and Fourth Quarter 2014 Results SAN JOSE, Calif., February 12, 2015 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its full year and fourth quarter ended December 31, 2014. Full Year 2014 Results For
February 11, 2015	SC 13G	IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G Passive Investment SC 13G 1 v401249sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) February 10, 2
February 4, 2015	SC 13G/A	IMI / Intermolecular, Inc. / MUBADALA DEVELOPMENT CO PJSC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss415251sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement
December 30, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
December 19, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
November 20, 2014	SC 13G/A	IMI / Intermolecular, Inc. / Cmea Ventures Vi Lp - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) DECEMBER 31, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu
November 17, 2014	SC 13G	IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) NOVEMBER 10, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th
October 31, 2014	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 2014 2013 Revenue: Collaborative development program a EX-99.1 2 a8-k2014q3xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Third Quarter 2014 Financial Results SAN JOSE, Calif., Oct. 31, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its third quarter ended September 30, 2014. Revenue for the third quarter of 2014 was $10.9 million
October 31, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
October 31, 2014	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
October 14, 2014	EX-99.1	3011 North First Street, San Jose, CA 95134 (408) 582-5700 / (408) 582-5401 fax Intermolecular Appoints Dr. Bruce McWilliams as President and Chief Executive Officer SAN JOSE, Calif. – October 13, 2014 - Intermolecular, Inc. (Nasdaq: IMI)— accelerating research and development for semiconductor and clean energy industries—today announced that Dr. Bruce McWilliams has been appointed President and Chief Executive Officer. David Lazovsky has resigned as President and Chief Execu
October 14, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
October 14, 2014	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
August 1, 2014	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2014 2013 2014 2013 Revenue: Collaborative development program and services Exhibit 99.1 Intermolecular Announces Second Quarter 2014 Financial Results SAN JOSE, Calif., August 1, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its second quarter ended June 30, 2014. Revenue for the second quarter of 2014 was $9.9 million, a decline of 40% from $16.6 million in
August 1, 2014	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 2, 2014	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 20, 2014	SC 13G/A	IMI / Intermolecular, Inc. / Raging Capital Management, LLC Passive Investment SC 13G/A 1 sc13ga10773804204302014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S
May 19, 2014	EX-99.1	SANDISK AND TOSHIBA TAKE EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY IN MEMORY TECHNOLOGY DEVELOPED WITH INTERMOLECULAR SANDISK AND TOSHIBA TAKE EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY IN MEMORY TECHNOLOGY DEVELOPED WITH INTERMOLECULAR SAN JOSE, Calif.
May 19, 2014	8-K	Other Events 8-K 1 a8-kxsandiskandtoshibaexer.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction
May 8, 2014	8-K	Current Report 8-K 1 a8-kreductioninforce.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
May 6, 2014	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended March 31, 2014 2013 Revenue: Collaborative development program and services revenue $ 8,886 $ 10,903 Product r Exhibit 99.1 Intermolecular Announces First Quarter 2014 Financial Results Key Technologies for Advanced Memory and LED Near Customer Commercialization in 2014 SAN JOSE, Calif., May 6, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended March 31, 2014. Revenue for the
May 6, 2014	8-K	Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 18, 2014	DEF 14A	- DEF 14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 18, 2014	DEFA14A	- DEF 14A DEFA14A 1 a2014proxycoverpage.htm DEF 14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confident
April 9, 2014	8-K	Current Report 8-K 1 a8-kxsjaggicompensationupd.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdicti
April 3, 2014	SC 13G	IMI / Intermolecular, Inc. / INTERMOLECULAR INC - SC 13G Passive Investment SC 13G 1 schedule13glazovsky2014.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d‑102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d‑1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d‑2 (Amendment No. )* INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 4
March 10, 2014	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated March 10, 2014 (including amendments thereto) with respect to the Common Stock of Intermolecular, Inc. This Joint Filing Agreement shall be filed as an Exh
March 10, 2014	S-8	- S-8 S-8 1 s8registrationstatement-fe.htm S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3
March 10, 2014	10-K	Intermolecular 10-K (Annual Report) 10-K 1 a10k-20131231.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
March 10, 2014	SC 13G	IMI / Intermolecular, Inc. / Raging Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 10 9 (CUSIP Number) Fe
February 27, 2014	EX-99.1	Intermolecular Announces New Developments in the SanDisk/Toshiba Relationship EX-99.1 2 ex9918ksandisktoshiba.htm EXHIBIT Intermolecular Announces New Developments in the SanDisk/Toshiba Relationship SAN JOSE, Calif. - February 27, 2014 - Intermolecular, Inc. (NASDAQ: IMI) today announced that the development activity related to the Collaborative Development Program (“CDP”) agreement with SanDisk and Toshiba has reached its successful conclusion. “The objective of the CDP w
February 27, 2014	8-K	Other Events 8-K 1 a8k-sandisktoshibafebruar.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi
February 25, 2014	SC 13G/A	IMI / Intermolecular, Inc. / ATMI INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2014	SC 13G/A	IMI / Intermolecular, Inc. / Cmea Ventures Vi Lp - SC 13G/A Passive Investment SC 13G/A 1 d675623dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check t
February 14, 2014	SC 13G/A	IMI / Intermolecular, Inc. / Park West Asset Management LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 interm13gam2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) C
February 13, 2014	SC 13G/A	IMI / Intermolecular, Inc. / MUBADALA DEVELOPMENT CO PJSC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss203130sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement
February 10, 2014	SC 13G/A	IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v367479sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2013 (Date o
February 6, 2014	8-K	Current Report 8-K 1 a8kguardianxamendment3.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdictio
February 6, 2014	8-K	Current Report 8-K 1 a8kgfamendment3.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
February 6, 2014	8-K	Results of Operations and Financial Condition 8-K 1 a8-k2013q4earningsreductio.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi
February 6, 2014	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended December 31, Years Ended December 31, 2013 2012 2013 2012 Revenue: Collaborative development program and servi EX-99.1 2 a8-k2013q4xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Full Year and Fourth Quarter 2013 Results Company implements corporate restructuring to improve operations SAN JOSE, Calif., February 6, 2014 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its full year and fourth q
December 31, 2013	8-K	Current Report 8-K 1 a8-kxguardianamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdicti
December 30, 2013	8-K	Current Report 8-K 1 a8-kxatmiamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction o
December 30, 2013	8-K	Current Report 8-K 1 a8-kxfirstsolaramendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdic
December 4, 2013	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
October 24, 2013	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Revenue: Collaborative development program a EX-99.1 2 a8-k2013x1024xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Third Quarter 2013 Financial Results Financial Results Ahead of Guidance, Internal R&D Pipeline Being Primed for Future CDP Growth SAN JOSE, Calif., October 24, 2013 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for
October 24, 2013	8-K	Results of Operations and Financial Condition 8-K 1 a8-k2013x1024xearningsrele.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi
October 22, 2013	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File
October 7, 2013	8-K/A	Financial Statements and Exhibits 8-K/A 1 a8-kaforrickneely.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or
October 3, 2013	8-K	Current Report 8-K 1 a8-kuctt.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo
October 2, 2013	EX-10.1	[Employee Proprietary Information and Inventions Agreement] August 22, 2013 C. Richard Neely, Jr. 259 Prince Street Los Gatos, CA 95032 Re: INTERMOLECULAR, INC. OFFER LETTER Dear Rick: INTERMOLECULAR, INC. (the “Company”) is pleased to offer you the position of Senior Vice President & Chief Financial Officer (CFO) of the Company, reporting to the CEO. You will be based at Company’s offices in San Jose, California. As the CFO, you will perform the duties cu
October 2, 2013	EX-99.1	INTERMOLECULAR NAMES SEMICONDUCTOR INDUSTRY VETERAN RICK NEELY CFO Mr. Neely Brings More than 30 Years of Financial and Operations Management Experience from Leading High-Tech Companies EX-99.1 3 ex991rickneelypressrelease.htm EXHIBIT INTERMOLECULAR NAMES SEMICONDUCTOR INDUSTRY VETERAN RICK NEELY CFO Mr. Neely Brings More than 30 Years of Financial and Operations Management Experience from Leading High-Tech Companies SAN JOSE, Calif. - October 2, 2013 - Intermolecular, Inc. (NASDAQ: IMI) today announced that it has named C. Richard (Rick) Neely, Jr. as the company’s chief financi
October 2, 2013	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File N
September 19, 2013	EX-4.1	AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK EX-4.1 2 ex41-amendmenttowarrant.htm EXHIBIT AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK This Amendment to Warrant to Purchase Shares of Common Stock (this “Amendment”) is made and entered into as of the last date of signature of the parties below, and amends that certain Warrant to Purchase Shares of Common Stock issued on March 15, 2010 (the “Warrant”) by Intermolecular, Inc., a Dela
September 19, 2013	8-K	Current Report 8-K 1 a8-kforwarrantamendments.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi
August 20, 2013	8-K	Current Report 8-K 1 a8k-russiapressrelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction
August 7, 2013	CORRESP	- August 7, 2013 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.
August 2, 2013	8-K	Current Report 8-K 1 a8-kreedinterimcfo.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I
July 25, 2013	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2013 2012 2013 2012 Revenue: Collaborative development program and services Exhibit 99.1 Intermolecular Announces Second Quarter 2013 Financial Results Early Stage CDP with Tier One Customer Marks Entry into $80 Billion Display Market SAN JOSE, Calif., July 25, 2013 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its second quarter ended June 30, 2013. Revenue for th
July 25, 2013	8-K	Results of Operations and Financial Condition 8-K 1 a8-kearningsq22013.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In
June 18, 2013	8-K	Current Report 8-K 1 globalfoundriesamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction
June 7, 2013	8-K	Current Report 8-K 1 a8-keidelman.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpora
June 3, 2013	EX-10.1	LOAN AND SECURITY AGREEMENT EX-10.1 2 svbintermolecularxloanand.htm EXHIBIT LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of May , 2013 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and INTERMOLECULAR, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties
June 3, 2013	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 a8-ksvbagreement.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor
May 31, 2013	8-K	Current Report 8-K 1 a8-kvotingresults.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco
April 25, 2013	8-K	Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
April 25, 2013	EX-99.1	Intermolecular, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts, Unaudited) Three Months Ended March 31, 2013 2012 Revenue: Collaborative development program and services revenue $ 10,903 $ 12,195 Product Exhibit 99.1 Intermolecular Announces First Quarter 2013 Financial Results Recent CDP and IP Agreements with Micron and Epistar -Further Expanding in Memory, and Diversifying into LED SAN JOSE, Calif., April 25, 2013 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended Marc
April 17, 2013	8-K	Current Report 8-K 1 a8-kmicronapril2013.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of
April 17, 2013	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu
April 17, 2013	DEF 14A	- DEF 14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 17, 2013	DEFA14A	- DEFA14A DEFA14A 1 a2013proxy.htm DEFA14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for

IMI / Intermolecular, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)